Raagini Jawa, MD, MPH, FASAM

Dr. Jawa is a clinician investigator at the Center for Research on Health Care at the University of Pittsburgh School of Medicine. She earned her MD-MPH from Boston University and is triple board-certified in internal medicine, infectious diseases, and addiction medicine.

Dr. Jawa's clinical work experiences has included providing co-located HIV primary care, office-based addiction treatment for patients with infectious complications of drug use at major academic medical centers, and complex inpatient management of endovascular and serious bacterial infectious complications of drug use. Her clinical interests include developing novel models of care delivery for people with substance use disorders: low barrier clinics, co-located specialty clinics, integrated care in community settings.

She leads the Harm Reduction Research Collaborative, a lab dedicated to integrating harm reduction into healthcare settings, advocating for evidence-based drug policy reform, and advancing patient-centered care for people who use drugs. She also serves on the Board of Directors for AMERSA, the PA Harm Reduction Network, and Prevention Point Pittsburgh.

Dr. Jawa was awarded a NIDA K12 to evaluate harm reduction service implementation across Pennsylvania Centers of Excellence. Her current research, supported by a NIDA K23 HEAL Initiative Career Development Award in Implementation Science, is a Hybrid Type 3 trial titled "Prescribe to Prevent HIV," which aims to help outpatient addiction clinics support safer drug use and prevent HIV and other serious infections.

Dr. Jawa has led academic lectures on implementing harm deduction interventions and preventing infectious complications associated with drug use across the country. She is also passionate about mentoring medical and public health trainees, particularly in designing and evaluating innovative addiction medicine and community-based harm reduction curricula for early-stage medical education and multidisciplinary teams.